Prestige Consumer Healthcare Inc.

Thank you for standing by, and welcome to Prestige Consumer Healthcare's third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. To remove yourself from the queue, you may press star 1-1 again. I would now like to hand the call over to Phil Turpilelli. Vice President, Investor Relations, and Treasury. Please go ahead.

Thanks, Operator, and thank you to everyone who has joined today. On the call with me are Ron Lombardi, our Chairman, President, and CEO, and Christine Sacco, our CFO and COO. On today's call, we'll review our third quarter fiscal 2025 results, discuss our full year outlook, and then take questions from analysts. A slide presentation accompanies today's call can be accessed by visiting PrestigeConsumerHealthcare.com, clicking on the Investors link, and then on today's webcast and presentation. Remember, some of the information contained in the presentation today includes non-GAAP financial measures. Reconciliations to the nearest GAAP financial measures are included in our earnings release and slide presentation. On today's call, management will make forward-looking statements around risks and uncertainties, which are detailed in a complete safe harbor disclosure on page two of the slide presentation that accompanies the call. These are important to review and contemplate. Business environment uncertainty remains heightened due to supply chain constraints, evolving US and international tariffs, and inflation, which have numerous potential impacts. This means results could change at any time and the forecasted impact of risk considerations is the best estimate based on the information available as of today's date. Further information concerning risk factors and cautionary statements are available in our most recent SEC filings and most recent company 10-K. And I'll hand it over to our CEO, Ron Lombardi. Ron? Thanks, Phil.

Let's begin on slide five. Our solid third quarter results exceeded the expectations we communicated back in November and resulted in both record quarterly sales and EPS. Net sales of 290 million increased nearly 3% versus the prior year and was above our forecast. We experienced continued strong international growth, including for the Hydrolyte brand, coupled with broad-based growth across nearly all of our North American categories. This included year-over-year growth in the Summer's Eve brand within the women's health category, as well as sequential sales improvement for ClearEyes. Earnings increased sharply in Q3 by 15% to a record quarterly EPS of $1.22, reflecting our strong sales growth, a stable gross margin, and disciplined capital deployment that's led to both lower interest expense and share count. Lastly, our strong free cash flow continues to enable capital deployment options that we use to enhance shareholder value. In Q3, we reduced our variable term loan debt balance to zero and continued to opportunistically repurchase shares while improving our leverage ratio to two and a half times. Chris will discuss our financial profile and go forward capital priorities in greater detail later on. Now let's turn to page six for a review of our GI category. Our fast-growing GI business represents nearly one-fifth of North American sales. The category features wide-ranging GI solutions that are shown on the left of the page. The portfolio is headlined by three iconic GI brands, Dramamine, Fleet, and Gaviscon. Each solves for unique consumer needs and leverages our wide assortment of brand building capabilities to drive long-term growth. Dramamine is synonymous with motion sickness and nausea categories. It recently celebrated its 75th anniversary and continues to remain the clear market defining brand. Our sales continue to grow nicely through a combination of engaging marketing, featuring our Drama Llama that encourages consumers to ditch the drama, as well as consistent innovation. Our most recent innovation includes Dramamine Advanced Herbals, which features ingredients specifically designed to help consumers deal with nausea and stress. Next, the Fleet brand is a clear market leader with 100-plus year history since its creation by Charlie Brown Fleet. Today, it stands with over a 50% share of the rectal laxative category. The brand's core assortment of enemas and suppositories provide rapid constipation relief for consumers when they need it most. We're also successfully leveraging the brand's deep consumer trust to expand into adjacent categories such as oral laxatives, where consumers know and trust the Fleet brand for laxative relief in other forms. This expansion builds naturally on the brand's longstanding heritage. Lastly, our Gaviscon brand in Canada continues to grow nicely with targeted marketing and consistent innovation that we discussed in detail last quarter. So in summary, our wide-ranging portfolio of leading GI brands have time-tested brand building that is used to drive long-term growth in their own unique ways. The formula continues to work, driving solid mid-single-digit growth over the last three years in total, and has set us up well for future success. With that, I'll turn it over to Chris to discuss the financials.